Gilead Announces Senior Management Promotion

Dr. Cheng joined Gilead in 1999 and most recently served as Vice President, Clinical Research, overseeing clinical development activities for the company's development-stage programs in HIV/AIDS. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. He received his medical degree and PhD in Cellular and Molecular Biology from Columbia University and undergraduate degree from the Johns Hopkins University.

"Over the past decade, Andrew has played a key leadership role overseeing multiple clinical programs, including pivotal studies supporting the approval of our HIV medications and clinical program design for our investigational HIV candidate, elvitegravir, and our novel pharmacoenhancer, GS 9350," commented Dr. Bischofberger. "With a growing number of programs currently in our research and development pipeline and the increasing complexity of our business, Andrew's new role will help us maintain an efficient and cost-effective approach to development, enhancing collaboration across our four therapeutic areas and ensuring we can advance promising candidates as quickly as possible."

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead, please call the Gilead Public Affairs Department at1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.

SOURCE: Gilead Sciences, Inc.

Gilead Sciences, Inc.Patrick O'Brien, Investors, 650-522-1936Amy Flood, Media, 650-522-5643